506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment

NCT00004239 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped poor accrual

Conditions

Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions

DRUG: Compound 506U78

Sponsor

Alliance for Clinical Trials in Oncology

Collaborators

[object Object]